RA Capital Management, a multi-stage investment manager, led a $60m Series A round in Curevo Vaccine, a clinical-stage biotechnology company, focused on bringing new generation adjuvanted subunit vaccines to market, with participation from Adjuvant Capital, Janus Henderson Investors, EN Investment, and GC Pharma. “As investors primarily focused on vaccines, we were impressed by Curevo’s encouraging Phase 1 data and unique sub-unit vaccine technology platform. The opportunity to bring the first non-live varicella (chickenpox) vaccine to the global community with Curevo’s vaccine technology was also a key motivator behind our investment in the company,” Charlie Petty, Adjuvant Capital Co-Founder and Principal.